{"id":68200,"date":"2026-06-15T21:02:35","date_gmt":"2026-06-15T13:02:35","guid":{"rendered":"https:\/\/flcube.com\/?p=68200"},"modified":"2026-06-15T21:02:36","modified_gmt":"2026-06-15T13:02:36","slug":"jazz-pharmaceuticals-reports-phase-3-lagoon-trial-misses-primary-endpoint-for-zepzelca-in-relapsed-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68200","title":{"rendered":"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jazz Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/JAZZ:NASDAQ\">NASDAQ: JAZZ<\/a>)<\/strong> announced on June 12, 2026 that the <strong>Phase 3 LAGOON trial<\/strong>, conducted by <strong>PharmaMar<\/strong>, failed to meet its <strong>primary endpoint of overall survival (OS)<\/strong> evaluating <strong>Zepzelca (lurbinectedin)<\/strong> as monotherapy or in combination with <strong>irinotecan<\/strong> compared to investigators&#8217; choice of <strong>topotecan or irinotecan<\/strong> in patients with <strong>relapsed (second-line) metastatic small cell lung cancer (SCLC)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results-lagoon-study\" class=\"wp-block-heading\">Clinical Trial Results \u2013 LAGOON Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Not met \u2013 Overall Survival (OS)<\/td><\/tr><tr><td><strong>Treatment Arms<\/strong><\/td><td>Zepzelca monotherapy vs. Zepzelca + irinotecan vs. investigator&#8217;s choice (topotecan\/irinotecan)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Relapsed (second-line) metastatic SCLC<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>No new safety signals identified; consistent with known profiles of each agent<\/td><\/tr><tr><td><strong>Trial Status<\/strong><\/td><td>Completed with negative top-line results<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-current-indications\" class=\"wp-block-heading\">Product Profile &amp; Current Indications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Lurbinectedin \u2013 alkylating drug that binds guanine residues within DNA<\/li>\n\n\n\n<li><strong>Origin:<\/strong> Discovered and developed by Spain-based PharmaMar<\/li>\n\n\n\n<li><strong>Current FDA Approvals:<\/strong><\/li>\n\n\n\n<li><strong>June 2020:<\/strong> Monotherapy for metastatic SCLC with disease progression after platinum-based chemotherapy<\/li>\n\n\n\n<li><strong>October 2025:<\/strong> Combination with atezolizumab \u00b1 hyaluronidase-tqjs as maintenance treatment for extensive-stage SCLC (ES-SCLC) without progression after first-line induction therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-rights-structure\" class=\"wp-block-heading\">Commercial Rights Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Territory<\/th><th>Rights Holder<\/th><th>Scope<\/th><\/tr><\/thead><tbody><tr><td><strong>North America<\/strong><\/td><td>Jazz Pharmaceuticals<\/td><td>Commercial rights<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>Luye Pharma Group<\/td><td>Exclusive development and commercialization rights (via April 2019 licensing deal with PharmaMar)<\/td><\/tr><tr><td><strong>Rest of World<\/strong><\/td><td>PharmaMar<\/td><td>Retained rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-analysis\" class=\"wp-block-heading\">Market Impact Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SCLC Treatment Landscape:<\/strong> Second-line SCLC remains challenging with limited effective options beyond topotecan<\/li>\n\n\n\n<li><strong>Zepzelca Positioning:<\/strong> Despite LAGOON failure, existing approvals maintain Zepzelca&#8217;s role in both relapsed and maintenance settings<\/li>\n\n\n\n<li><strong>Commercial Implications:<\/strong> Negative trial results may limit expansion into second-line monotherapy or combination regimens<\/li>\n\n\n\n<li><strong>Investor Response:<\/strong> Stock impact likely muted given Zepzelca&#8217;s established revenue streams from current indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-context-amp-future-development\" class=\"wp-block-heading\">Strategic Context &amp; Future Development<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The LAGOON trial results represent a setback in Jazz&#8217;s strategy to expand Zepzelca&#8217;s utility in the <strong>relapsed SCLC setting<\/strong>, where the drug was already approved as monotherapy based on earlier single-arm studies. However, the <strong>October 2025 approval for maintenance therapy in ES-SCLC<\/strong> provides a significant growth opportunity, as this represents a larger patient population in the first-line setting.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Second-Line SCLC:<\/strong> Topotecan remains standard of care despite modest efficacy<\/li>\n\n\n\n<li><strong>Maintenance Therapy:<\/strong> Zepzelca + atezolizumab combination competes in the emerging maintenance space for ES-SCLC<\/li>\n\n\n\n<li><strong>Pipeline Competition:<\/strong> Multiple novel agents in development for SCLC, including antibody-drug conjugates and targeted therapies<\/li>\n\n\n\n<li><strong>Biomarker Development:<\/strong> Lack of predictive biomarkers for lurbinectedin response limits precision medicine approaches<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps-amp-corporate-strategy\" class=\"wp-block-heading\">Next Steps &amp; Corporate Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Data Analysis:<\/strong> Full results presentation expected at upcoming medical conferences<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Focus on maintaining current approvals rather than pursuing additional indications in relapsed setting<\/li>\n\n\n\n<li><strong>Commercial Focus:<\/strong> Prioritize growth in maintenance therapy indication approved in October 2025<\/li>\n\n\n\n<li><strong>Partnership Dynamics:<\/strong> Continue collaboration with PharmaMar and Luye Pharma for global development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory strategy, and commercial expectations. Actual results may differ due to risks including competitive dynamics, market adoption, and future clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68201,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,2368,4290],"class_list":["post-68200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-jazz-pharmaceuticals","tag-nasdaq-jazz"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial, conducted by PharmaMar, failed to meet its primary endpoint of overall survival (OS) evaluating Zepzelca (lurbinectedin) as monotherapy or in combination with irinotecan compared to investigators&#039; choice of topotecan or irinotecan in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68200\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer\" \/>\n<meta property=\"og:description\" content=\"Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial, conducted by PharmaMar, failed to meet its primary endpoint of overall survival (OS) evaluating Zepzelca (lurbinectedin) as monotherapy or in combination with irinotecan compared to investigators&#039; choice of topotecan or irinotecan in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68200\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T13:02:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T13:02:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1506.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer\",\"datePublished\":\"2026-06-15T13:02:35+00:00\",\"dateModified\":\"2026-06-15T13:02:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200\"},\"wordCount\":482,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1506.webp\",\"keywords\":[\"Clinical trial results\",\"Jazz Pharmaceuticals\",\"NASDAQ: JAZZ\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68200#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68200\",\"name\":\"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1506.webp\",\"datePublished\":\"2026-06-15T13:02:35+00:00\",\"dateModified\":\"2026-06-15T13:02:36+00:00\",\"description\":\"Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial, conducted by PharmaMar, failed to meet its primary endpoint of overall survival (OS) evaluating Zepzelca (lurbinectedin) as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68200\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1506.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1506.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68200#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial, conducted by PharmaMar, failed to meet its primary endpoint of overall survival (OS) evaluating Zepzelca (lurbinectedin) as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68200","og_locale":"en_US","og_type":"article","og_title":"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer","og_description":"Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial, conducted by PharmaMar, failed to meet its primary endpoint of overall survival (OS) evaluating Zepzelca (lurbinectedin) as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC).","og_url":"https:\/\/flcube.com\/?p=68200","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T13:02:35+00:00","article_modified_time":"2026-06-15T13:02:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1506.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68200#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68200"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer","datePublished":"2026-06-15T13:02:35+00:00","dateModified":"2026-06-15T13:02:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68200"},"wordCount":482,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68200#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1506.webp","keywords":["Clinical trial results","Jazz Pharmaceuticals","NASDAQ: JAZZ"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68200#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68200","url":"https:\/\/flcube.com\/?p=68200","name":"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68200#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68200#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1506.webp","datePublished":"2026-06-15T13:02:35+00:00","dateModified":"2026-06-15T13:02:36+00:00","description":"Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial, conducted by PharmaMar, failed to meet its primary endpoint of overall survival (OS) evaluating Zepzelca (lurbinectedin) as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68200#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68200"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68200#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1506.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1506.webp","width":1080,"height":608,"caption":"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68200#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1506.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68200"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68200\/revisions"}],"predecessor-version":[{"id":68202,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68200\/revisions\/68202"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68201"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}